A good news for Odisha. The Institute of Medical Sciences and SUM Hospital has been chosen by the Indian Council for Medical Research (ICMR) for undertaking human clinical trials of India’s first COVID-19 vaccine.
SUM Hospital is one of 13 medical institutes in the country and the only in Odisha to be chosen as a clinical trial site for the much-awaited vaccine. Prof. E. Venkat Rao of Community Medicine department of the hospital will be the principal investigator during the trial.
According to the report, ICMR has partnered with Bharat Biotech International Limited (BBIL) to fast track clinical trials of the indigenous COVID-19 vaccine - BBV152, which has been derived from a strain of SARS-CoV- 2 isolated by the National Institute of Virology, Pune. Phase-I and Phase-II human trials of the vaccine have been approved by the Drug Controller General of India.
IMS and SUM Hospital, a 1600-bed teaching hospital with 40 departments, is among 13 medical institutes in the country identified by ICMR to take up the clinical trial. The trial will commence after approval of the Institutional Ethical Committee (IEC) of the hospital. Convalescent plasma therapy involves the use of antibodies from the blood of patients who have recovered from Covid-19 to treat other infected persons. Dr. Chandan Das, Professor in Medicine, will be in charge of the convalescent plasma therapy in the hospital.
This hospital is a private medical college established in 2007. The motto of this hospital is to imparting quality medical education. It is affiliated to SOA deemed to be university, Bhubaneswar.
Comments
Post a Comment